Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients with metastatic melanoma (CHECKMATE-067). Here we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Selby, Mark J., Engelhardt, John J., Johnston, Robert J., Lu, Li-Sheng, Han, Minhua, Thudium, Kent, Yao, Dapeng, Quigley, Michael, Valle, Jose, Wang, Changyu, Chen, Bing, Cardarelli, Pina M., Blanset, Diann, Korman, Alan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017747/
https://www.ncbi.nlm.nih.gov/pubmed/27610613
http://dx.doi.org/10.1371/journal.pone.0161779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017747/
https://www.ncbi.nlm.nih.gov/pubmed/27610613
http://dx.doi.org/10.1371/journal.pone.0161779

Ejemplares similares